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Summary
Background Neonates born to women infected with HIV are at increased risk for invasive group B streptococcus 
(GBS) disease. We aimed to compare safety and immunogenicity of trivalent glycoconjugate GBS vaccine in pregnant 
women with and without HIV in Malawi and South Africa.
Methods In our non-randomised phase 2, open-label, multicentre study, we recruited pregnant women attending 
two antenatal clinics, one in Blantyre, Malawi, and one in Soweto, Johannesburg, South Africa. Participants were 
divided into three groups on the basis of their HIV infection status (no infection, infection and high CD4 cell count 
[>350 cells per μL], and infection and low CD4 cell count [>50 to ≤350 cells per μL]) and received a 5 μg dose of 
glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM₁₉₇ [Novartis Vaccines, Siena, Italy]) intramuscularly 
at 24–35 weeks’ gestation. GBS serotype-speciﬁ c antibody concentrations were measured before vaccination (day 1), 
day 15, day 31, and at delivery, and in infants at birth and day 42 of life. The primary outcomes were safety in mothers 
and infants and the amount of placental transfer of GBS serotype-speciﬁ c antibodies from mothers to their infants. 
All immunogenicity and safety analyses were done on the full analysis set, including participants who, or whose 
mother, correctly received the vaccine and who provided at least one valid assessable serum sample. This study is 
registered with ClinicalTrials.gov, number NCT01412801.
Findings 270 women and 266 infants were enrolled between Sept 26, 2011, and Dec 4, 2012 (90 women and 87 infants 
without HIV, 89 and 88 with HIV and high CD4 cell counts, and 91 and 91 with HIV and low CD4 cell counts, 
respectively). Seven women were lost to follow-up, six withdrew consent, one died, and two relocated. Eight infants 
died or were stillborn and two were lost to follow-up. Across serotypes, fold change in antibody concentrations were 
higher for the HIV-uninfected group than the HIV-infected groups. Transfer ratios were similar across all three 
groups (0·49–0·72; transfer ratio is infant geometric mean antibody concentration in blood collected within 72 h of 
birth divided by maternal geometric mean antibody concentration in blood collected at delivery); however, at birth, 
maternally derived serotype-speciﬁ c antibody concentrations were lower for infants born to women infected with HIV 
(0·52–1·62 μg/mL) than for those born to women not infected with HIV (2·67–3·91 μg/mL). 151 (57%) of 265 women 
reported at least one solicited adverse reaction: 39 (45%) of 87 women with HIV and low CD4 cell counts, 52 (59%) of 
88 women with HIV and high CD4 cell counts, and 60 (67%) of 90 women in the HIV-uninfected group. 49 (18%) of 
269 women had at least one adverse event deemed possibly related to the vaccine (six [7%] in the HIV and low CD4 
cell count group, 12 [13%] in the HIV and high CD4 cell count group, and 21 [23%] in the HIV-uninfected group), as 
did three (1%) of 266 neonates (zero, two [1%], and one [1%]); none of these events was regarded as serious.
Interpretation The vaccine was less immunogenic in women infected with HIV than it was in those not infected, 
irrespective of CD4 cell count, resulting in lower levels of serotype-speciﬁ c maternal antibody transferred to infants, 
which could reduce vaccine protection against invasive GBS disease. A validated assay and correlate of protection is 
needed to understand the potential protective value of this vaccine.
Funding Novartis Vaccines and Diagnostics division (now part of the GlaxoSmithKline group of companies), Wellcome 
Trust UK, Medical Research Council: Respiratory and Meningeal Pathogens Research Unit.
Copyright © Heyderman et al. Open Access article distributed under the terms of CC BY.
Introduction
Several African countries including Malawi, Liberia, and 
Ethiopia have met their Millennium Development Goals 
for child mortality reduction; however, neonatal deaths 
caused by infections, preterm birth, and birth asphyxia 
account for 44% of mortality for children younger than 
5 years.1 Group B streptococcus (GBS) has been identiﬁ ed 
as a leading cause of neonatal sepsis and meningitis in 
several countries across sub-Saharan Africa,2 and is 
therefore a crucial target for public health intervention. In 
Africa, the reported incidence of early-onset invasive GBS 
disease varies across studies from 0 to 2·1 per 
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1000 livebirths, whereas late-onset invasive GBS disease 
varies from 0 to 0·89 per 1000 livebirths, with case fatality 
rates ranging from 13% to 46%.2 Intrapartum antibiotic 
prophylaxis has substantially reduced, although not 
eliminated, early-onset invasive GBS disease in 
high-income countries.3 Intrapartum antibiotic pro-
phylaxis is diﬃ  cult to implement in resource-poor 
settings and has little eﬀ ect on the incidence of late-onset 
invasive GBS disease.4
Glycoconjugate vaccines against other capsulated 
bacteria, such as Neisseria meningitidis, Streptococcus 
pneumoniae, and Haemophilus inﬂ uenzae type b, have 
proved highly eﬀ ective in many settings.5–7 Because 
neonatal GBS disease develops rapidly after birth, 
administration of a glycoconjugate GBS vaccine to 
infants is unlikely to prevent disease and therefore 
maternal immunisation during pregnancy has been 
identiﬁ ed as the best strategy to prevent both 
early-onset and late-onset invasive GBS disease, and 
therefore possibly to reduce the incidence of stillbirth 
and miscarriage.8 Maternal immunisation against 
other diseases, such as tetanus, has proved highly 
eﬀ ective and acceptable in many low-income and 
middle-income countries.9,10
About 5·3% of pregnant women in sub-Saharan Africa 
are thought to be infected with HIV, and although eﬀ orts 
to prevent mother-to-child transmission across the 
continent are having an eﬀ ect, rates of neonatal exposure 
to HIV remain high.11 Neonates born to women infected 
with HIV are at increased risk for invasive GBS disease 
in high-income and middle-income countries.12,13 The 
risk for late-onset invasive GBS disease (occurring in 
neonates aged between 7 and 90 days) is 3·18 to 19 times 
greater in neonates born to mothers infected with HIV 
than in those born to mothers not infected with HIV, 
and the risk for early-onset GBS disease (occurring in 
neonates aged <7 days) is 1·7 times greater.13–15 A study11 
in Belgium reported that 1·55% of infants born to 
mothers infected with HIV developed invasive GBS 
disease, compared with 0·08% of infants born to 
mothers not infected with HIV over the same time 
period. Similarly, a study15 in South Africa reported the 
incidence of invasive GBS disease to be higher in infants 
exposed to HIV (4·46 per 1000 livebirths) compared with 
infants not exposed to HIV (1·98 per 1000 livebirths). 
The increased susceptibility to invasive GBS disease in 
neonates born to women infected with HIV, despite 
most of these babies not being infected with HIV, is 
probably due to lower concentrations of naturally 
acquired serotype-speciﬁ c capsular antibodies and 
reduced transplacental transfer in mother–newborn 
dyads in which the mother is infected with HIV than in 
dyads in which the mother is not infected.15 Response to 
vaccination is known to be impaired in individuals with 
HIV infection.16 A previous trial17 of three doses (0·5 μg, 
2·5 μg, and 5·0 μg) of a glycoconjugate GBS trivalent 
vaccine in women not infected with HIV in South Africa 
showed that the vaccine was well tolerated and 
immunogenic.
In the present study, we explore the hypothesis that 
HIV infection aﬀ ects the safety and immunogenicity of 
the 5·0 μg formulation of GBS vaccine in pregnant 
women and their infants in Malawi and South Africa. 
We aimed to assess placental transfer of GBS 
serotype-speciﬁ c antibodies in patients with and without 
HIV, as well as post-vaccination concentrations in 
mothers and safety.
Methods
Study design
This non-randomised phase 2, open-label, multicentre 
study was done in two antenatal clinics, one in Blantyre, 
Malawi, and one in Soweto, Johannesburg, South Africa, 
between September, 2011, and December, 2012. Pregnant 
Research in context
Evidence before this study
We searched PubMed and Web of Science for studies on group B 
streptococcus (GBS) vaccines published before Dec 1, 2015, 
using the search terms “Group B Streptococcus vaccine” and 
combinations thereof. We did not ﬁ nd any previous GBS 
vaccines that had been tested on pregnant women infected 
with HIV, and no published research on CRM₁₉₇-conjugated GBS 
vaccines in human beings.
Added value of this study
This is the ﬁ rst study investigating the safety and immunogenicity 
of a candidate glycoconjugate GBS vaccine in pregnant women 
infected with HIV and their infants, and shows that the vaccine is 
both immunogenic and has a good safety proﬁ le, although it was 
less immunogenic in women infected with HIV. The study also 
adds to previous evidence of the safety and immunogenicity of 
GBS vaccines in healthy pregnant and non-pregnant women, in 
earlier clinical trials. This is the ﬁ rst GBS vaccine immunogenicity 
study to be done on the African continent that has included 
participants from outside South Africa.
Implications of all the available evidence
Given that GBS is a leading cause of neonatal sepsis and 
meningitis across sub-Saharan Africa, this vaccine oﬀ ers a 
potential pathway to reduce infection-related neonatal death 
and disability in high-burden settings. However, since the 
vaccine was less immunogenic in women infected with HIV 
than in those not infected, irrespective of CD4 cell count, 
validated correlates of protection need to be identiﬁ ed to 
improve understanding of the potential protective value of this 
GBS vaccine for pregnant women and their infants, particularly 
in high HIV seroprevalence countries. 
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women were enrolled sequentially by study nurses into 
three groups in a 1:1:1 ratio on the basis of their HIV 
infection status and CD4 cell count until each of the 
groups was ﬁ lled; the groups were HIV uninfected, HIV 
infected with a high CD4 cell count (>350 cells per μL), 
and HIV infected with a low CD4 cell count (>50 to 
≤350 cells per μL).
The study was done in accordance with the Declaration 
of Helsinki and the International Council for 
Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use Guidelines for Good 
Clinical Practice. Written informed consent was obtained 
from women before enrolment. The protocol was 
approved by the National Health Sciences Research 
Committee (Malawi) and the University of Witwatersrand, 
Human Research Ethics Committee (South Africa). 
Use of an investigational GBS vaccine was approved by 
the Pharmacy, Medicines & Poisons Board, Malawi, and 
the Medicine Control Council, South Africa.
Participants
Pregnant women aged 18–40 years between 24 and 
35 weeks’ gestation were eligible. All women attending 
the clinics at the study sites were informed of the study. 
Those who fulﬁ lled the study eligibility criteria and 
agreed to take part were enrolled after giving informed 
written consent. Women infected with HIV were eligible 
if their CD4 cell count was more than 50 cells per μL and 
they had WHO stage I or II disease. Exclusion criteria 
included receipt of a vaccine 15 days before enrolment 
(except tetanus toxoid and non-alum adjuvanted 
inﬂ uenza vaccines); severe allergic reaction or 
hypersensitivity to previous vaccinations or vaccine 
component; fever at enrolment or acute infection up to 
7 days before enrolment; any disorder associated with 
prolonged bleeding; immunosuppressive treatment 
within 30 days before enrolment; receipt of blood or 
blood products in the 12 weeks before enrolment; 
behavioural or cognitive impairment; and progressive or 
severe neurological disorder, seizure disorder, epilepsy, 
or Guillain-Barré syndrome. Twin pregnancies were 
included in the study (appendix). Carriage of GBS was 
not assessed or deemed an exclusion criterion for this 
study. Treatment of mothers and their babies, including 
HIV management, was provided by government services 
according to national guidelines, free at the point of care.
Gestational age was estimated by (in order of 
preference) ultrasonography before 24 weeks’ gestation, 
date of last menstrual period, fundal height at 
20–35 weeks’ gestation, or ultrasonography at 
25–27 weeks’ gestation. CD4 cell counts were assessed 
using BD FACSCount (BD Biosciences, San Jose, CA, 
USA) and viral load was measured in Malawi using the 
Abbott RealTime HIV-1 assay (Abbott Laboratories, 
Abbott Park, IL, USA), and in South Africa using the 
Taqman version 2 HIV-1 assay (Roche, Pleasanton, 
CA, USA).
Procedures
Women were immunised with a 0·5 mL dose of non-
adjuvanted CRM₁₉₇-conjugated GBS vaccine (Novartis 
Vaccines, Siena, Italy) containing 5 μg of each capsular 
polysaccharide of serotypes Ia, Ib, and III, reconstituted 
in 0·9% sodium chloride. The vaccine was given 
intramuscularly into the non-dominant arm at 
24–35 weeks’ gestation. For immunogenicity analysis, 
blood was collected from women before vaccination on 
day 1, at days 15 and 31 post-vaccination, and at delivery. 
For women infected with HIV, HIV-1 viral load and CD4 
cell counts were measured before vaccination and the 
day of delivery. Cord blood or peripheral blood was 
collected from infants at birth and day 42.
GBS serotype-speciﬁ c antibody concentrations in 
women and infants were estimated using a previously 
described ELISA protocol at GlaxoSmithKline Clinical 
Sciences Laboratory, Marburg, Germany.18 In brief, 
antibody concentrations were assessed using 96-well 
plates, which were coated in 1 μg/mL human serum 
albumin-conjugated GBS polysaccharide representing 
the three vaccine serotypes. Serially diluted serum 
samples were incubated on the coated plates for 1 h 
at 37°C and an alkaline-phosphatase-conjugated goat 
anti-human IgG secondary antibody was added after 
washing and incubated for a further 90 min. After 
further washing, SeramunGelb pNPP was added to the 
plates and incubated for 30 min at room temperature, 
then the reaction was stopped with SeramunGelb stop. 
Antibody concentrations were calculated using 
Mikrowin 2000 software from optical density values 
measured at 405 nm using a BEP III ELISA processor. 
Because of lab constraints, serotype Ia ELISA testing 
was done in three batches, whereas all the testing for 
serotype Ib and III was done in one batch. Antibody 
concentrations were expressed as geometric mean 
concentrations (GMCs) with 95% CIs, calculated with 
the Clopper-Pearson method. Subgroup analysis was 
done for women on the basis of baseline serotype-
speciﬁ c antibody titres.
Outcomes
The primary objective of this study was to compare the 
amount of placental transfer of GBS serotype-speciﬁ c 
antibodies to the infants of pregnant women infected 
with HIV and those not infected after administration of 
investigational GBS vaccine. As a secondary objective, 
the concentrations of maternal serotype-speciﬁ c GBS 
antibodies were assessed post-vaccination. An exploratory 
objective was the assessment of the kinetics of maternally 
derived antibodies in infants born to vaccinated women. 
Safety objectives were the assessment of solicited adverse 
reactions, unsolicited adverse events, serious adverse 
events, and obstetric outcomes.
After immunisation, the women were observed for 
30 min for any immediate adverse reactions. Adverse 
events and serious adverse events were graded on severity 
See Online for appendix
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and possible relation to study vaccine by the investigator. 
A standardised approach was used to identify adverse 
events, which were deﬁ ned as any untoward medical 
occurrence in a mother given the investigational vaccine 
or her infant that did not necessarily have a causal 
relation with this treatment. Solicited adverse reactions 
were recorded for 7 days post-vaccination with diary 
cards. Adverse events were collected up to day 31 post-
vaccination, and adverse events requiring a physician’s 
visit, serious adverse events, and deaths were recorded 
for women and infants throughout the study. As part of 
the safety analysis the outcome of the pregnancy was 
assessed, including the health status of neonates 
(including Apgar score). Admission to hospital for a 
normal delivery was not deemed a serious adverse event 
in the context of this study.
Statistical analysis
The sample sizes were calculated on the conservative 
assumption that only 60 participants per group would be 
enrolled, that there would be a 15% dropout rate, and 
that 80% of women would deliver infants that are at 
37 weeks or more of gestation or weighed 2500 g or 
more at birth. Thus, a sample size of 40 per group would 
give about 95% power to detect an 8% diﬀ erence in the 
percentage of placental transfer between any two study 
groups. However, if the maximum number of 
participants per group (90) were to be reached, under the 
Figure: Study proﬁ le
Most participants who did not complete the study were from the Malawi site, with the exception of the two women who relocated: one woman in the high CD4 cell count group who was lost to 
follow-up after delivery and one infant in the high CD4 cell count group who died between birth and day 42. 
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same assumptions for the dropout rate and for the 
percentage of babies born at 37 weeks or more of 
gestation or weighing 2500 g or more at birth, the 
number of assessable participants would increase up to 
60 per group, giving about 95% power to detect a 6·5% 
diﬀ erence in the percentage of placental transfer 
between any two study groups. After determination of 
the sample size for the trial with and without babies 
born at less than 37 weeks’ gestation or less than 2500 g, 
we decided that both of these early gestation or 
underweight groups should be retained within the 
analysis. All serum analyses were done on the full 
analysis set, which included all mothers who correctly 
received the vaccine and who provided at least one valid 
assessable serum sample, and their neonates. Safety 
data were analysed descriptively for the safety set, which 
included all mothers who correctly received the study 
vaccination and who provided safety data, and their 
neonates.
The primary objective was analysed using an ANCOVA 
model on log₁₀-transformed maternal and infant GBS 
antibody levels, with HIV group and country as qualitative 
factors, and gestational age at delivery and birthweight as 
covariates. Multiplicity of testing across the three participant 
groups was adjusted for by using a signiﬁ cance level of 
0·016 (ie, p=0·05/3). The null hypothesis was rejected if a 
signiﬁ cant diﬀ erence was seen for all three serotypes. The 
secondary objective was analysed using an ANCOVA on 
log₁₀-transformed maternal antibody concentrations at 
each relevant timepoint, with HIV group and country 
as qualitative factors, and baseline log₁₀-antibody 
concentration as a covariate. Infant antibody concentrations 
at each timepoint were analysed using an ANOVA model, 
with maternal HIV group and country as qualitative factors 
and a signiﬁ cance level of 0·05.
For analysis, any antibody concentrations that were 
below the lower limit of quantiﬁ cation (<LLQ) were set as 
half the LLQ (LLQ serotype Ia: 0·326 μg/mL, serotype Ib: 
0·083 μg/mL, serotype III: 0·080 μg/mL). All statistical 
analyses were done with SAS version 9.1.
This study is registered with ClinicalTrials.gov, number 
NCT01412801.
Role of funding source
The study sponsor was involved in all stages of the study, 
including manuscript development. The corresponding 
author had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication. All authors agreed to submit the manuscript 
for publication. No honorarium, grant, or other form of 
payment was provided to authors, with the exception of 
funding needed to do the study.
Results
Of 398 women screened across two sites in Malawi and 
South Africa, 270 women and their infants were enrolled 
in the study between Sept 26, 2011, and Dec 4, 2012: 
90 without HIV (45 from each country), 89 with HIV and 
high CD4 cell counts (44 from Malawi and 45 from 
South Africa), and 91 with HIV and low CD4 cell counts 
(46 from Malawi and 45 from South Africa; ﬁ gure). 
254 (94%) women completed the study across the 
three groups; seven were lost to follow-up, six withdrew 
consent, one died, and two relocated away from the study 
area. 256 (96%) of 266 infants enrolled completed the 
study across the groups. 270 mothers were enrolled in 
the study but only 260 remained in the study at delivery, 
ﬁ ve of whom had twins, resulting in 265 livebirths. 
One mother died during labour and had a stillbirth that 
was included in the enrolled infants (n=266). Reasons for 
withdrawal were death or stillbirth (n=8), and loss to 
follow-up (n=2).
Baseline characteristics for women and infants were 
similar across the groups, although, consistent with the 
natural history of HIV acquisition in these populations, 
women in the HIV-uninfected group were younger than 
those in the HIV-infected groups (table 1). No notable 
diﬀ erences in demographics existed between sites except 
that the maternal median body-mass index was higher in 
all groups in South Africa (26·8–29·3 kg/m²) compared 
with Malawi (22·8–24·7 kg/m²). As expected, viral loads 
were higher in mothers infected with HIV and low CD4 
cell counts than they were in those with high CD4 cell 
counts. Because most women who were not already 
receiving antiretroviral treatment were given treatment 
HIV-infected, low 
CD4 cell count
HIV-infected, high 
CD4 cell count
HIV-uninfected
Women
n 91 89 90
Age (years) 28·0 (18–39) 28·0 (18–38) 24·0 (18–39)
Black, n (%) 91 (100%) 89 (100%) 90 (100%)
Body-mass index (kg/m²) 26·0 (17·9–48·7) 24·8 (16·0–43·5) 25·8 (20·3–43·4)
Time from vaccination to delivery (weeks) 11 (1–19) 10 (0–18) 9 (1–17)
Gestational age at vaccination (weeks) 27·0 (22–35) 29·0 (23–35) 29·5 (24–34)
CD4 cell count at baseline (cells per μL) 233 (55–348); n=89 478 (352–1099) NA
CD4 cell count at delivery (cells per μL) 262 (30–988); n=81 502 (30–1326); n=80 NA
Viral load at baseline (RNA copies per mL) 2760 (20–814 356); 
n=90
305 (20–334 981); 
n=88
NA
Viral load at delivery (RNA copies per mL) 75 (20–240 965); 
n=80
75 (20–729 085); 
n=81
NA
Baseline HAART, n (%) 51 (56%) 47 (53%) NA
Infants
n 91 88 87
Male sex, n (%) 49 (54%) 48 (55%) 46 (53%)
Gestational age at birth (weeks) 39 (27–42) 38 (29–44) 39 (29–42)
Premature (<37 weeks), n (%) 19 (21%) 25 (28%) 14 (16%)
Early premature* (<32 weeks), n (%) 3 (3%) 2 (2%) 1 (1%)
Low birthweight (≤2·5 kg), n (%) 12 (13%)* 7 (8%)* 9 (10%)
Data are presented as the median and range unless stated otherwise and are from the full analysis set. NA=not applicable. 
HAART=highly active antiretroviral treatment.*Two (2%) infants in each group were of very low birthweight (≤1·5 kg).
Table 1: Demographics and baseline characteristics of enrolled participants
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during the study, viral load decreased between screening 
and delivery in both HIV-infected groups. Rates of 
premature birth for the HIV-uninfected group were 
similar to those reported for sub-Saharan Africa, and 
were higher in HIV-infected groups.19
Rates of women reporting at least one solicited adverse 
reaction were highest in the HIV-uninfected group 
(60 [67%] of 90 women), compared with the low CD4 cell 
count (39 [44%] of 88 women) and high CD4 cell count 
(52 [59%] of 88 women) groups. Most reactions were 
grade 2 or less, with 4% or less of participants reporting 
a severe reaction for any of the solicited adverse reactions 
(table 2). Local reactions were reported by 18–39% of 
women across the groups, and 40–59% reported 
systemic reactions. The most frequently reported local 
adverse reaction was injection site pain, with severe pain 
being reported by two (2%) of 87 women with HIV and 
low CD4 cell count group and four (4%) of 90 in the 
HIV-uninfected group (table 2). The most often reported 
systemic adverse reactions were fatigue and headache, 
which were reported most frequently by women without 
HIV and least by those with HIV and low CD4 cell 
counts (table 2).
The percentage of women reporting adverse events was 
similar across the three groups, with 74–78% reporting at 
least one adverse event (table 3). Of these, 7–23% were 
deemed to be at least possibly related to the study vaccine. 
Serious adverse events were reported by 28–32% of 
women, but none were deemed to be caused by the study 
vaccine. Similarly, no diﬀ erences in reporting of adverse 
events were seen across the infant groups. 41–49% of 
infants reported adverse events and 18–19% reported 
serious adverse events (table 3), none of which was 
deemed to be caused by vaccination. One woman with 
HIV in the high CD4 cell count group died from uterine 
rupture and her infant was stillborn (appendix). 
Seven other infant deaths occurred in the study, mostly 
in Malawi; no deaths in the study were deemed to be 
caused by the study vaccine (table 3, appendix).
No diﬀ erences in obstetric outcomes and pregnancy 
events were recorded across the three groups (appendix). 
No association between vaccine administration and 
change in viral load was seen in the HIV-infected groups.
For all groups, GMCs of antibodies were higher 
post-vaccine than at baseline at all tested timepoints 
(table 4). The highest responses were seen in the 
HIV-uninfected group, for which ratios between baseline 
HIV-infected, low 
CD4 cell count 
(90 women and 
91 infants)
HIV-infected, high 
CD4 cell count 
(89 women and 
88 infants)
HIV-uninfected 
(90 women and 
87 infants)
Women
Any adverse event 67 (74%) 68 (76%) 70 (78%)
Adverse event possibly related to vaccine 6 (7%) 12 (13%) 21 (23%)
Serious adverse event* 25 (28%) 28 (31%) 29 (32%)
Adverse event leading to participant 
withdrawing from the trial
0 1 (1%) 0
Medically attended adverse event 42 (47%) 44 (49%) 49 (54%)
Death† 0 1 (1%) 0
Infants
Any adverse event 37 (41%) 43 (49%) 37 (43%)
Adverse event possibly related to vaccine 0 2 (2%) 1 (1%)
Serious adverse event* 17 (19%) 16 (18%) 16 (18%)
Adverse event leading to participant 
withdrawing from the trial
4 (4%) 2 (2%) 2 (2%)
Medically attended adverse event 21 (23%) 29 (33%) 21 (24%)
Death† 4 (4%) 2 (2%) 2 (2%)
*No serious adverse events were deemed to be at least possibly related to vaccination. †See appendix for details of deaths.
Table 3: Number of women and infants reporting unsolicited adverse events and serious adverse events
HIV-infected, 
low CD4 cell 
count (n=87)
HIV-infected, 
high CD4 cell 
count (n=88)
HIV-uninfected 
(n=90)
Local
Any local 16 (18%) 26 (30%) 35 (39%)
Ecchymosis 0 0 1 (1%)
Erythema 0 1 (1%) 1 (1%); n=89
Induration 0 1 (1%) 0
Swelling 0 0 2 (2%)
Pain
Any 16 (18%) 26 (30%) 35 (39%)
Severe 2 (2%) 0 4 (4%)
Systemic
Any systemic 35 (40%) 48 (55%) 53 (59%) 
Chills
Any 8 (9%) 12 (14%) 20 (22%)
Severe 1 (1%) 1 (1%) 0
Nausea
Any 11 (13%) 15 (17%) 20 (22%); n=89
Severe 1 (1%) 0 2 (2%); n=89
Malaise
Any 9 (10%) 17 (19%) 21 (23%)
Severe 1 (1%) 0 1 (1%)
Myalgia 7 (8%) 15 (17%) 21 (23%)
Arthralgia
Any 11 (13%) 20 (23%) 26 (29%)
Severe 0 0 1 (1%)
Headache
Any 21 (24%) 28 (32%) 39 (43%)
Severe 1 (1%) 1 (1%) 2 (2%)
Fatigue
Any 21 (24%) 27 (31%) 42 (47%)
Severe 2 (2%) 1 (1%) 3 (3%)
Rash 3 (3%) 1 (1%) 1 (1%)
Fever (≥38oC) 3 (3%) 0 0
For local adverse reactions, no participants reported severe reactions (>100 mm), 
with the exception of pain. Data are given for local reactions (≥25 mm).
Table 2: Number of women reporting local and systemic adverse 
reactions during the ﬁ rst 7 days after vaccination
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and delivery against the three serotypes were 15·0 μg/mL 
(Ia), 9·14 μg/mL (Ib), and 30 μg/mL (III); whereas these 
were 7·21 μg/mL (Ia), 4·83 μg/mL (Ib), and 9·99 μg/mL 
(III) for the low CD4 cell count group; and 8·78 μg/mL 
(Ia), 7·34 μg/mL (Ib), and 8·65 μg/mL (III) for the high 
CD4 cell count group. The biggest diﬀ erences between 
women infected and not infected with HIV were 
reported against serotype III. No diﬀ erence in 
immunogenicity was reported between mothers in the 
high and low CD4 cell count groups. Despite diﬀ erences 
in magnitude, the kinetics of the antibody response in 
women infected and not infected with HIV (table 4), and 
the variation in individual responses were similar across 
groups (appendix). Antibody concentrations at baseline 
were undetectable (<LLQ) for about 69–80% of women 
against serotype Ia (72 in the low CD4 cell count, 66 in 
high CD4 cell count, and 62 in HIV-uninfected groups), 
1–6% of women against serotype Ib (one in the low CD4 
cell count, one in high CD4 cell count, and ﬁ ve in 
HIV-uninfected groups), and 34–43% of women against 
serotype III (22 in the low CD4 cell count, 33 in high 
CD4 cell count, and 33 in HIV-uninfected groups). 
Because too few participants had antibody concentrations 
below the LLQ against serotype Ib, subgroup analysis 
was only done on serotypes Ia and III. When stratiﬁ ed 
by baseline antibody concentration (<LLQ or ≥LLQ), 
diﬀ erences in antibody GMCs between the 
HIV-uninfected and HIV-infected groups against 
serotypes Ia and III were less pronounced for women 
with undetectable GBS antibody concentrations at 
baseline. Antibody GMCs post-vaccination were higher 
in those who had detectable antibody concentrations at 
HIV-infected, 
low CD4 cell count
HIV-infected, 
high CD4 cell count
HIV-uninfected Low CD4 vs 
high CD4
Low CD4 vs 
HIV-uninfected
High CD4 vs 
HIV-uninfected
Serotype Ia
Data available, n 74 75 77 ·· ·· ··
Geometric mean antibody concentration (μg/mL)
Day 1 pre-vaccination 0·24 (0·19–0·30) 0·25 (0·20–0·32) 0·38 (0·30–0·48) p=0·709 p=0·007 p=0·019
Day 15 post-vaccination 2·62 (1·64–4·17) 2·95 (1·86–4·69) 5·61 (3·56–8·84) p=0·713 p=0·023 p=0·053
Day 31 post-vaccination 2·68 (1·74–4·10) 3·26 (2·14–4·98) 6·63 (4·37–10) p=0·513 p=0·003 p=0·020
Delivery 2·22 (1·50–3·29) 2·69 (1·82–3·98) 4·49 (3·06–6·60) p=0·493 p=0·013 p=0·067
Geometric mean ratio to day 1
Day 15 8·36 (5·27–13) 9·54 (6·02–15) 19 (12–30) p=0·690 p=0·011 p=0·032
Day 31 8·55 (5·60–13) 11 (6·91–16) 23 (15–35) p=0·492 p=0·001 p=0·010
Delivery 7·21 (4·88–11) 8·78 (5·95–13) 15 (10–22) p=0·479 p=0·007 p=0·046
Serotype Ib
Data available, n 44 53 66 ·· ·· ··
Geometric mean antibody concentration (μg/mL)
Day 1 pre-vaccination 0·51 (0·38–0·70) 0·36 (0·27–0·48) 0·40 (0·31–0·51) p=0·104 p=0·205 p=0·652
Day 15 post-vaccination 2·93 (1·73–4·95) 3·50 (2·17–5·65) 6·07 (3·98–9·26) p=0·617 p=0·035 p=0·090
Day 31 post-vaccination 2·62 (1·62–4·24) 3·68 (2·38–5·70) 5·35 (3·63–7·87) p=0·300 p=0·024 p=0·209
Delivery 2·12 (1·36–3·31) 3·04 (2·03–4·56) 3·84 (2·69–5·50) p=0·236 p=0·042 p=0·392
Geometric mean ratio to day 1
Day 15 6·87 (4·08–12) 8·23 (5·12–13) 14 (9·36–22) p=0·611 p=0·033 p=0·089
Day 31 6·11 (3·79–9·85) 8·70 (5·63–13) 13 (8·56–19) p=0·277 p=0·021 p=0·211
Delivery 4·83 (3·10–7·52) 7·34 (4·90–11) 9·14 (6·38–13) p=0·165 p=0·029 p=0·425
Serotype III
Data available, n 53 55 70 ·· ·· ··
Geometric mean antibody concentration (μg/mL)
Day 1 pre-vaccination 0·12 (0·09–0·17) 0·10 (0·07–0·14) 0·14 (0·10–0·18) p=0·407 p=0·572 p=0·145
Day 15 post-vaccination 1·24 (0·79–1·95) 1·52 (0·97–2·36) 5·90 (3·99–8·72) p=0·528 p<0·0001 p<0·0001
Day 31 post-vaccination 1·51 (0·97–2·35) 1·31 (0·85–2·02) 5·35 (3·66–7·83) p=0·643 p<0·0001 p<0·0001
Delivery 1·25 (0·81–1·94) 1·07 (0·70–1·65) 3·80 (2·61–5·55) p=0·616 p=0·0002 p<0·0001
Geometric mean ratio to day 1
Day 15 9·85 (6·25–16) 12 (7·64–18) 47 (32–70) p=0·555 p<0·0001 p<0·0001
Day 31 12 (7·70–19) 10 (6·62–16) 43 (29–63) p=0·599 p<0·0001 p<0·0001
Delivery 9·99 (6·44–15) 8·65 (5·65–13) 30 (21–44) p=0·638 p=0·0002 p<0·0001
Data are geometric means (95% CI), unless otherwise stated. p values for pairwise comparisons are given in the last three columns (ANCOVA).
Table 4: Maternal geometric mean antibody concentrations and ratios to baseline
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baseline, with GMCs at delivery of 18–61 μg/mL across 
groups for serotype Ia and 1·8–8·8 μg/mL for 
serotype III, compared with GMCs of 1·0–1·8 μg/mL 
and 0·4–1·1 μg/mL for the same serotypes for women 
who had undetectable antibody concentrations at 
baseline (appendix). Ratios of antibody GMCs to baseline 
could not be accurately calculated for this analysis 
because of the high frequency of women below the LLQ 
at baseline. For serotype Ia, a site diﬀ erence in response 
was recorded, with women in South Africa having much 
higher baseline and vaccine-induced antibody responses 
than the women in Malawi, across the HIV-infected and 
HIV-uninfected groups (appendix).
Placental GBS serotype-speciﬁ c antibody transfer 
ratios were similar between HIV-uninfected and 
HIV-infected groups for each serotype (0·49–0·72; 
table 5). Infant antibody GMCs followed the same 
pattern as maternal antibody GMCs, with infants in the 
HIV-uninfected group having higher GMCs at birth and 
day 42 than those in HIV-infected groups (table 5). Rates 
of antibody decay from day 1 to day 42 were similar 
across the three groups, with geometric mean ratios 
over this period of 0·50–0·58 for serotype Ia, 0·28–0·56 
for serotype Ib, and 0·31–0·40 for serotype III.
Discussion
In this small phase 2 trial in high disease burden settings 
in Malawi and South Africa, we showed the trivalent 
GBS vaccine to be well tolerated by pregnant women 
irrespective of HIV status, and have not identiﬁ ed any 
concerning safety signals in these women or their 
infants. The vaccine was substantially more 
immuno genic in women not infected with HIV than it 
was in those with the infection, and generated antibody 
GMCs to serotypes Ib and III similar to those recorded 
previously in pregnant women given this vaccine (GMCs 
at delivery from a previous study18 in Belgium and 
Canada: 2·41 μg/mL for serotype Ib and 1·90 μg/mL for 
serotype III). However, antibody GMCs against serotype 
Ia in mothers not infected with HIV in the present study 
were substantially lower than those recorded for the 
same vaccine dose in a previous study17 of women not 
infected with HIV in South Africa (4·49 μg/mL for the 
HIV-uninfected group in the present study compared 
with ﬁ ve times higher values for the group receiving the 
equivalent vaccine dose in the previous South African 
study). Carriage was not measured in the present study, 
but previous reports suggest that although South Africa 
and Malawi have similar prevalence in carriage isolates 
for serotype Ib (6·7% [South Africa] and 6·2% [Malawi]) 
and III (37% [South Africa] and 39% [Malawi]), they do 
have diﬀ erent prevalence for serotype Ia (30% [South 
Africa] and 18% [Malawi]).20,21 In our study, of women not 
infected with HIV, ten (22%) of 45 in Malawi and 
18 (40%) of 45 in South Africa had antibody GMCs more 
than or equal to the LLQ against serotype Ia at baseline, 
whereas in the low and high CD4 cell count groups, the 
numbers of women with GMCs in these ranges were 
two (4%) of 45 versus one (2%) of 44 in Malawi, and 
16 (36%) of 45 versus 22 (49%) of 45 in South Africa, 
which might be due to this diﬀ erence in carriage. 
However, the diﬀ erence between these countries for 
serotype Ia should be interpreted with caution because 
of the small numbers of women in each group. We saw 
no similar patterns for the other two serotypes in our 
study. Although these studies had no major 
HIV-infected, low CD4 cell 
count
HIV-infected, high CD4 cell count HIV-uninfected Low CD4 vs 
high CD4
Low CD4 vs 
HIV-uninfected
High CD4 vs 
HIV-uninfected
n Data n Data n Data
Serotype Ia
Transfer ratio* 79 0·58 (0·49–0·69) 79 0·60 (0·51–0·72) 83 0·72 (0·61–0·85) p=0·755 p=0·089 p=0·169
GMC day 1 (μg/mL) 79 1·01 (0·66–1·56) 81 1·22 (0·80–1·87) 83 3·91 (2·56–5·96) p=0·548 p<0·0001 p=0·0002
GMC day 42 (μg/mL) 81 0·61 (0·41–0·89) 83 0·64 (0·44–0·94) 79 1·97 (1·33–2·91) p=0·848 p<0·0001 p<0·0001
GMR day 42:day 1 70 0·58 (0·50–0·67) 78 0·50 (0·44–0·57) 75 0·50 (0·44–0·58) p=0·296 p=0·344 p=0·925
Serotype Ib
Transfer ratio* 41 0·51 (0·38–0·69) 54 0·64 (0·50–0·83) 57 0·49 (0·38–0·63) p=0·251 p=0·796 p=0·131
GMC day 1 (μg/mL) 44 1·31 (0·78–2·19) 56 1·62 (1·03–2·56) 57 2·67 (1·70–4·20) p=0·537 p=0·040 p=0·125
GMC day 42 (μg/mL) 75 0·29 (0·19–0·44) 70 0·44 (0·29–0·68) 67 1·16 (0·75–1·80) p=0·174 p<0·0001 p=0·002
GMR day 42:day 1 34 0·28 (0·20–0·38) 46 0·35 (0·27–0·46) 46 0·56 (0·42–0·73) p=0·297 p=0·0006 p=0·008
Serotype III
Transfer ratio* 53 0·60 (0·44–0·82) 44 0·51 (0·36–0·72) 66 0·56 (0·43–0·75) p=0·515 p=0·791 p=0·670
GMC day 1 (μg/mL) 54 0·60 (0·36–0·99) 51 0·52 (0·31–0·88) 66 3·88 (2·47–6·10) p=0·713 p<0·0001 p<0·0001
GMC day 42 (μg/mL) 77 0·21 (0·14–0·31) 80 0·15 (0·10–0·22) 77 0·86 (0·58–1·28) p=0·258 p<0·0001 p<0·0001
GMR day 42:day 1 43 0·39 (0·32–0·49) 46 0·40 (0·33–0·49) 59 0·31 (0·26–0·38) p=0·574 p=0·186 p=0·051
95% CIs are given in parenthesis. p values for pairwise comparisons are given in the last three columns (ANOVA for transfer ratio and ANCOVA for geometric mean antibody concentrations and GMRs). 
GMC=geometric mean antibody concentrations. GMR=ratio of GMCs to baseline. *Transfer ratio=infant GMC in blood collected within 72 h of birth divided by maternal GMC in blood collected at delivery.
Table 5: Infant antibody GMCs, GMRs, and mean placental transfer ratios
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methodological diﬀ erences between the assays used, 
these data emphasise the need to have an internationally 
standardised assay for the assessment of the response to 
GBS conjugate vaccines.
In Malawi and South Africa, 18–30% of pregnant 
women are infected with HIV and their infants are 
exposed to HIV.22,23 Since HIV infection has been shown 
to reduce vaccine eﬃ  cacy for a number of vaccines 
irrespective of CD4 cell counts,16 the lower immune 
response seen in the HIV positive groups compared with 
the uninfected group is unsurprising. This impaired 
response in individuals infected with HIV has also been 
seen for other conjugate vaccines.24
Antibody transfer ratios from mother to infant were 
similar across the HIV-infected and HIV-uninfected 
groups, and were similar to those ratios reported in 
previous trials25,26 of this vaccine, and for other 
glycoconjugate vaccines given to pregnant mothers. 
A previous candidate conjugate GBS vaccine against 
serotype III led to antibody transfer rates of 77%, which 
was slightly higher than those seen in our study.27 
Similarly, rates of antibody decay in infants were similar 
in our study to those seen in previous studies with 
candidate GBS vaccines; however, whether the antibody 
concentrations seen by day 42 would be suﬃ  cient to 
potentially protect against late-onset invasive GBS 
disease is not known. Baker and colleagues27 reported 
infant GBS serotype III-speciﬁ c antibody concentrations 
of 30% of those recorded at birth at 2 months of age, and 
previous studies18 with the study vaccine reported infant 
concentrations of 22–32% of birth levels at 3 months of 
age. Although the functionality of maternal antibodies 
was not measured in our study, previous research has 
shown that functional GBS antibodies can persist for up 
to 2 years post-immunisation.28 Future vaccine studies 
would need to assess opsonophagocytic activity in the 
infant, in conjunction with an established correlate of 
protection, to estimate potential infant protection. 
Additionally, further research should concentrate on the 
responses of women who had undetectable antibody 
concentrations at baseline and vaccine strategies that 
might be needed to potentially provide protection to 
infants born to these women.
The assessment of GBS vaccines as they reach late-phase 
development would be greatly enhanced if the 
concentration of maternal and neonatal GBS antibody 
that correlates with passive protection against neonatal 
disease could be deﬁ ned. Assay-speciﬁ c antibody 
concentrations have been adopted to predict protection for 
conjugate vaccines against H inﬂ uenzae type b and 
S pneumoniae, but although several thresholds for anti-
GBS antibody have been proposed on the basis of naturally 
acquired and vaccine-acquired immunity,29–31 these 
thresholds have not been widely accepted, particularly in 
an African setting, and the absence of a standardised assay 
across studies makes the selection of a reliable correlate of 
protection diﬃ  cult.32 A limitation of the immunogenicity 
testing in the present study is that the samples were 
analysed over a long period of time and multiple antigen 
lots, which could have contributed to the variation 
recorded. Several laboratories are working to generate a 
robust and widely applicable assay for approval by the 
regulatory authorities. Future larger scale studies should 
therefore focus on the use of a validated assay so that 
immunogenicity parameters can be readily compared 
between studies, countries, and over time. Our study is 
also limited by the small number of participants and the 
variation in baseline antibody concentrations, which led to 
diﬀ ering magnitudes of individual responses to 
vaccination. Additional, larger studies are needed that 
include clinically relevant endpoints such as carriage, 
invasive disease, and mortality, in the appropriate 
populations. Future research should also include analysis 
of the eﬀ ect of a booster vaccine dose, or a higher dose, on 
responses in pregnant women infected with HIV, or 
women with undetectable antibody concentrations at 
baseline.
In conclusion, the investigational glycoconjugate GBS 
vaccine was less immunogenic in women infected with 
HIV than those not infected, irrespective of CD4 cell 
count. The lower amounts of serotype-speciﬁ c maternal 
antibody transferred to the infants of women infected 
with HIV compared with those not infected could reduce 
vaccine protection from neonatal GBS. At present, this 
vaccine is undergoing further phase 2 trials and studies 
of antibody persistence in pregnant women. Once a 
validated, approved assay and a correlate of protection 
has been established, researchers will be better able to 
understand the potential protective value of this vaccine 
for pregnant women and their infants in high HIV 
seroprevalence countries.
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